FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rosol Michael Stanley				2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X_ Officer (give title below) Other (specify below)					
(Last) (First) (Middle) 4995 BRADENTON AVE., SUITE 240					3. Date of Earliest Transaction (Month/Day/Year) 01/14/2022									Chie	ef Medical O	fficer	
(Street) DUBLIN, OH 43017				4. If Amendment, Date Original Filed(Month/Day/Year)							/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	Exec	Deemed ution Date, if	(Instr. 8)		ction	4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5)			D) Beneficially Owned Following Reported Transaction(s)		ollowing	Form:	7. Nature of Indirect Beneficial	
				(Mon	nth/Day/	y ear)		ode	V	Amoun	(A) or (D)	Price	(Instr. 3 a	na 4)		Direct (D) Ownership or Indirect (I) (Instr. 4)	
Common	Stock (1)		01/14/2022				A	4		7,728	A	\$ 0	14,575			D	
Commor	Stock												6,816			I	Held by 401(k) Plan
			Table II -					quire	conta the fo	ained ir orm dis sposed o	this for plays a of, or Ben	m are curre eficial	not requesting ntly valid	OMB conf	spond unle trol numbe	ss	1474 (9-02)
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da	4. te, if Transaction Code ('ear) (Instr. 8)		tion)	5.					7. T Ame Und Secu	itle and ount of lerlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	Beneficial Ownershi (Instr. 4)
									Date	cisable	Expiratio	n Title	Amount or Number				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Rosol Michael Stanley 4995 BRADENTON AVE., SUITE 240 DUBLIN, OH 43017			Chief Medical Officer					

Signatures

/s/ Erika L. Eves for Michael S. Rosol, by power of attorney	01/18/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock issued under the Amended and Restated 2014 Stock Incentive Plan in lieu of cash bonus, as elected by the Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.